INTRODUCTION: In 5%-10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%-10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. RESULTS: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. CONCLUSION: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine.
展开▼
机译:简介:在5%-10%的家族性地中海热(FMF)患者中,秋水仙碱不能有效预防炎症发作。另有5%-10%的患者对有效剂量的秋水仙碱不耐受,并出现严重的副作用。尽管许多国家没有为这种适应症提供补偿,但抗白细胞介素-1(IL-1)药物的治疗可能是这些患者的替代选择。方法:我们系统地在PubMed,Web of Science和Scopus上搜索了FMF患者抗IL-1治疗的报道。结果:在284篇可能相关的文章中,鉴定出27篇合格报告,并将其纳入数据分析。结论:接受anakinra治疗的患者中有76.5%的患者接受治疗,而接受canakinumab治疗的患者中有67.5%的患者对治疗有完全反应。在患有AA型淀粉样变性病的患者中,抗IL-1治疗可逆转蛋白尿。对于没有反应或不能耐受秋水仙碱的FMF患者,抗IL-1治疗似乎是一种安全有效的替代方法。
展开▼